NCT02823405View on ClinicalTrials.gov

X4P-001 and Pembrolizumab in Patients With Advanced Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 15, 2016

Primary Completion Date

March 15, 2018

Study Completion Date

March 15, 2018

Conditions
Melanoma
Interventions
DRUG

X4P-001

X4P-001 100 mg capsules, administered orally, continuous daily dosing

DRUG

Pembrolizumab

Pembrolizumab 2 mg/kg, administered by IV infusion every 3 weeks

Trial Locations (4)

30322

Clinical Site, Atlanta

52242

Clinical Site, Iowa City

77030

Clinical Site, Houston

84112

Clinical Site, Salt Lake City

Sponsors

Lead Sponsor

X4 Pharmaceuticals
All Listed Sponsors
lead

X4 Pharmaceuticals

INDUSTRY

NCT02823405 - X4P-001 and Pembrolizumab in Patients With Advanced Melanoma | Biotech Hunter | Biotech Hunter